Pharma Pricing Congress

Hot topics in pharma and orphan drugs

By Christina Poschen I attended this year’s Pharma Pricing and Market Access Conference in London with attendees across the pharmaceutical industry, payer and HTA bodies and patient representatives. While following the talks, panel discussions and roundtable debates, a few overarching key topics crystallised: –          Germany – AMNOG changes AMNOG, the German pharmaceutical law is regularly adapted to changes in the …

Performance-based managed entry agreements for medicines: Much needed, but not feasible?

When payers see new and expensive therapies come to market with immature outcome data, they increasingly want to ‘pay for value’. That is, pricing and reimbursement (P&R) conditions should reward actual clinical performance and any potential cost savings achieved in real-world conditions. Despite increasingly frequent commentaries on the topic in the literature, progress towards value-based P&R has been slow across the …

Managed Care Benefit Management: Payer’s perspective on market access: tempering expectations

Dr. Anthony Bonagura of OptumHealth discusses payers’ perspective on market access and tempering expectations in his 2016 presentation ‘Managed Care Benefit Management‘. In this presentation, learn about benefit and coverage determination. Download this presentation to understand more about: The basics of coverage of a medical service/treatment under a medical insurance plan How a new product or services is evaluated Opportunities …

PBM Alliance with Walgreens seeks to lower drug costs, improve outcomes

Published Online: Sep 01,2016 Laurie Toich, Assistant Editor Drug costs have become a hot button issue throughout the healthcare and pharmaceutical industries, as patient outcomes and value-based care take center stage. The US Centers for Medicare and Medicaid Services has focused on both aspects of healthcare through proposed rules and payment models, among other cost-controlling actions. Executives at Prime Therapeutics, a …

Model N whitepaper

Five Critical Success Factors to Achieve Global Pricing Excellence in Life Sciences

2015 Annual Survey – Global Pricing in Life Sciences By Model N and High Point Solutions “The $US300 billion pharmaceuticals industry is undergoing a profound transformation. Cost containment initiatives by payers, governments and healthcare insurance organizations have created a challenging business environment with controlled pricing, promotion of generic alternatives and greater obstacles to bringing innovative drugs to market. With changing dynamics in the industry, achieving …

BioPharma Mexico - Emerging markets

Innovation in emerging markets

In the latest of his series of articles on emerging markets innovation (Nature Reviews Drug Discovery, Sept 2014; Nature Reviews Drug Discovery, Jan 2015; JMDS, June 2015; Drug Discovery Today, July 2015), Dr. Ajay Gautam has published a new study in the August issue of Nature Review Drug Discovery to review these markets at a granular, therapeutic area level. The …

“Planning for Reimbursement Success in Clinical Development”

Sven Kili of Sanofi Biosurgery joined us for Stem Cells & Regenerative Medicine Congress USA 2014 to present about ‘ Planning for Reimbursement Success in Clinical Development’.   Download his presentation now to understand more about: Focusing on value in planning and carrying out a clinical development plan Mechanisms to develop a value message Key opinion leader management and reimbursement planning Launch activities–focusing …

concentra, pharma, pricing, market access, data, visualisation

Download: Top 5 Pricing and Market Access Visualisations every pharmaceutical organisation needs

Analytics is a hot topic in pharmaceuticals and life sciences. Data visualisation is unlocking new understanding and value at all stages of the product lifecycle. Once the territory of the research and development process, big data analytics is now becoming the differentiator in commercial and operational decision making. How can you get the most out of your pricing and market …